SIRPA and neoplasm: Recent studies have shown that the CD47-SIRPα axis is a phagocytic checkpoint regulating macrophages and other innate immune cells, and a series of molecules that block the CD47-SIRPα axis are in clinical development for tumour therapy [13, 41].